Ovarian Cancer
Kancera AB’s oncology research includes ovarian cancer, with clinical activity centered on treatment-resistant disease settings and the management of relapse after prior platinum-based therapy.
- Recurrent epithelial ovarian cancer
- Platinum-sensitive relapse
- Gynecologic oncology
The sponsor’s clinical work in this area is directed toward patients with recurrent disease involving the ovary, supporting research in solid tumor oncology and anti-cancer therapeutics.
Fallopian Tube and Primary Peritoneal Cancer
Another key therapeutic area is recurrent epithelial fallopian tube cancer and primary peritoneal cancer, reflecting a focus on closely related malignancies within the gynecologic cancer spectrum.
- Recurrent epithelial fallopian tube cancer
- Primary peritoneal cancer
- Recurrent gynecologic malignancies
These studies address cancers that share clinical features with ovarian cancer and require specialized approaches within female reproductive system oncology.
Combination Cancer Therapy
Kancera AB is involved in research on combination therapy for recurrent gynecologic cancers, with attention to pairing investigational oncology agents with established chemotherapy backbones.
- Carboplatin-based regimens
- Therapeutic tolerability
- Oncology supportive treatment strategies
This area highlights interest in improving treatment options for patients whose disease has returned after prior standard therapy, particularly in the setting of recurrent solid tumors.
Clinical Pharmacology and Early Human Studies
The sponsor also funds early-stage clinical research in healthy volunteers, reflecting a therapeutic interest in the clinical characterization of new compounds and their tolerability in humans.
- Safety and tolerability assessment
- Pharmacokinetics
- Healthy volunteer studies
These investigations support the development of novel candidates in drug discovery and clinical pharmacology.
